JP2016524914A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016524914A5 JP2016524914A5 JP2016527005A JP2016527005A JP2016524914A5 JP 2016524914 A5 JP2016524914 A5 JP 2016524914A5 JP 2016527005 A JP2016527005 A JP 2016527005A JP 2016527005 A JP2016527005 A JP 2016527005A JP 2016524914 A5 JP2016524914 A5 JP 2016524914A5
- Authority
- JP
- Japan
- Prior art keywords
- hpv
- cells
- specific
- cell population
- fragments
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2019202239A JP7315435B2 (ja) | 2013-07-15 | 2019-11-07 | 抗ヒトパピローマウイルス抗原ｔ細胞の調製方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361846161P | 2013-07-15 | 2013-07-15 | |
| US61/846,161 | 2013-07-15 | ||
| PCT/US2014/046478 WO2015009604A1 (en) | 2013-07-15 | 2014-07-14 | Methods of preparing anti-human papillomavirus antigen t cells |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019202239A Division JP7315435B2 (ja) | 2013-07-15 | 2019-11-07 | 抗ヒトパピローマウイルス抗原ｔ細胞の調製方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016524914A JP2016524914A (ja) | 2016-08-22 |
| JP2016524914A5 true JP2016524914A5 (enExample) | 2017-08-31 |
| JP6616295B2 JP6616295B2 (ja) | 2019-12-04 |
Family
ID=51257632
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016527005A Active JP6616295B2 (ja) | 2013-07-15 | 2014-07-14 | 抗ヒトパピローマウイルス抗原ｔ細胞の調製方法 |
| JP2019202239A Active JP7315435B2 (ja) | 2013-07-15 | 2019-11-07 | 抗ヒトパピローマウイルス抗原ｔ細胞の調製方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019202239A Active JP7315435B2 (ja) | 2013-07-15 | 2019-11-07 | 抗ヒトパピローマウイルス抗原ｔ細胞の調製方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (8) | US20160144018A1 (enExample) |
| EP (3) | EP4137564B1 (enExample) |
| JP (2) | JP6616295B2 (enExample) |
| CN (2) | CN105452448B (enExample) |
| AU (4) | AU2014290286A1 (enExample) |
| CA (1) | CA2918080A1 (enExample) |
| ES (3) | ES2932429T3 (enExample) |
| RU (1) | RU2713333C2 (enExample) |
| WO (1) | WO2015009604A1 (enExample) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2015380397B2 (en) | 2015-01-31 | 2021-10-21 | The Trustees Of The University Of Pennsylvania | Compositions and methods for T cell delivery of therapeutic molecules |
| WO2017049237A1 (en) * | 2015-09-18 | 2017-03-23 | The General Hospital Corporation Dba Massachusetts General Hospital | Personalized approach to dosage of anti-fugetactic agent for treatment of cancer |
| JP7092662B2 (ja) * | 2015-10-30 | 2022-06-28 | チルドレンズ ナショナル メディカル センター | ナイーブｔ細胞集団からのｈｐｖ抗原特異的ｔ細胞の生成 |
| JP7019578B2 (ja) * | 2015-12-30 | 2022-02-15 | セルジーン コーポレイション | Ｔリンパ球の産生方法及びそれにより産生されるｔリンパ球 |
| KR20190062505A (ko) | 2016-10-03 | 2019-06-05 | 주노 쎄러퓨티크스 인코퍼레이티드 | Hpv-특이적 결합 분자 |
| CN110099998A (zh) | 2016-10-26 | 2019-08-06 | 艾欧凡斯生物治疗公司 | 冷冻保存的肿瘤浸润淋巴细胞的再刺激 |
| TWI788307B (zh) | 2016-10-31 | 2023-01-01 | 美商艾歐凡斯生物治療公司 | 用於擴增腫瘤浸潤性淋巴細胞之工程化人造抗原呈現細胞 |
| GB201700621D0 (en) | 2017-01-13 | 2017-03-01 | Guest Ryan Dominic | Method,device and kit for the aseptic isolation,enrichment and stabilsation of cells from mammalian solid tissue |
| CA3050299A1 (en) * | 2017-01-20 | 2018-07-26 | Atara Biotherapeutics, Inc. | Methods of treating multiple sclerosis using autologous t cells |
| US11254913B1 (en) | 2017-03-29 | 2022-02-22 | Iovance Biotherapeutics, Inc. | Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy |
| JOP20190224A1 (ar) | 2017-03-29 | 2019-09-26 | Iovance Biotherapeutics Inc | عمليات من أجل إنتاج الخلايا اللمفاوية المرتشحة للأورام واستخداماتها في العلاج المناعي |
| TW201919662A (zh) | 2017-06-05 | 2019-06-01 | 美商艾歐凡斯生物治療公司 | 對雙重難治性黑色素瘤使用腫瘤浸潤性淋巴細胞之方法 |
| US11952408B2 (en) | 2017-10-03 | 2024-04-09 | Juno Therapeutics, Inc. | HPV-specific binding molecules |
| US11713446B2 (en) | 2018-01-08 | 2023-08-01 | Iovance Biotherapeutics, Inc. | Processes for generating TIL products enriched for tumor antigen-specific T-cells |
| EP3737743A1 (en) | 2018-01-08 | 2020-11-18 | Iovance Biotherapeutics, Inc. | Processes for generating til products enriched for tumor antigen-specific t-cells |
| CN112566698A (zh) | 2018-04-05 | 2021-03-26 | 朱诺治疗学股份有限公司 | T细胞受体和表达该t细胞受体的工程化细胞 |
| CN112585276A (zh) | 2018-04-05 | 2021-03-30 | 朱诺治疗学股份有限公司 | 产生表达重组受体的细胞的方法和相关组合物 |
| CN112585277A (zh) | 2018-04-05 | 2021-03-30 | 朱诺治疗学股份有限公司 | 表达重组受体的t细胞、相关多核苷酸和方法 |
| WO2019196088A1 (en) | 2018-04-13 | 2019-10-17 | Syz Cell Therapy Co. | Methods of obtaining tumor-specific t cell receptors |
| WO2019210131A1 (en) | 2018-04-27 | 2019-10-31 | Iovance Biotherapeutics, Inc. | Closed process for expansion and gene editing of tumor infiltrating lymphocytes and uses of same in immunotherapy |
| WO2019217753A1 (en) | 2018-05-10 | 2019-11-14 | Iovance Biotherapeutics, Inc. | Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy |
| BR112021002390A2 (pt) | 2018-08-09 | 2021-05-11 | Juno Therapeutics Inc | processos para gerar células modificadas e suas composições |
| JP7504891B2 (ja) | 2018-09-11 | 2024-06-24 | ジュノー セラピューティクス インコーポレイテッド | 操作された細胞組成物のマススペクトロメトリー分析のための方法 |
| US12453697B2 (en) | 2018-11-05 | 2025-10-28 | Iovance Biotherapeutics, Inc. | Processes for production of tumor infiltrating lymphocytes and uses of the same in immunotherapy |
| BR112021008549A2 (pt) | 2018-11-05 | 2022-01-04 | Iovance Biotherapeutics Inc | Método de tratamento de carcinoma pulmonar de células não pequenas com uma população de linfócitos infiltrantes de tumor |
| GB201821207D0 (en) * | 2018-12-24 | 2019-02-06 | Tcer Ab | Immunotherapy therapy |
| CA3136737A1 (en) | 2019-05-01 | 2020-11-05 | Juno Therapeutics, Inc. | Cells expressing a recombinant receptor from a modified tgfbr2 locus, related polynucleotides and methods |
| JP2023507432A (ja) | 2019-12-20 | 2023-02-22 | インスティル バイオ （ユーケイ） リミテッド | 腫瘍浸潤リンパ球を単離するためのデバイスおよび方法ならびにそれらの使用 |
| EP4171616A1 (en) | 2020-06-26 | 2023-05-03 | Juno Therapeutics GmbH | Engineered t cells conditionally expressing a recombinant receptor, related polynucleotides and methods |
| CA3195019A1 (en) | 2020-10-06 | 2022-04-14 | Maria Fardis | Treatment of nsclc patients with tumor infiltrating lymphocyte therapies |
| JP2023554395A (ja) | 2020-12-17 | 2023-12-27 | アイオバンス バイオセラピューティクス，インコーポレイテッド | Ｃｔｌａ－４及びｐｄ－１阻害剤と併用した腫瘍浸潤リンパ球療法による治療 |
| EP4314253A2 (en) | 2021-03-25 | 2024-02-07 | Iovance Biotherapeutics, Inc. | Methods and compositions for t-cell coculture potency assays and use with cell therapy products |
| WO2023196884A1 (en) | 2022-04-06 | 2023-10-12 | Juno Therapeutics, Inc. | Detection assay for human papillomavirus (hpv) type 16 (hpv-16) |
| EP4507704A1 (en) | 2022-04-15 | 2025-02-19 | Iovance Biotherapeutics, Inc. | Til expansion processes using specific cytokine combinations and/or akti treatment |
| WO2026090040A1 (en) * | 2024-10-21 | 2026-04-30 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods of preparing cell therapy products for the treatment of conditions caused by human papillomavirus 6 or 11 infection |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8034334B2 (en) | 2002-09-06 | 2011-10-11 | The United States Of America As Represented By The Secretary, Department Of Health And Human Services | Immunotherapy with in vitro-selected antigen-specific lymphocytes after non-myeloablative lymphodepleting chemotherapy |
| CN1609196A (zh) * | 2003-10-17 | 2005-04-27 | 上海普泛生物科技有限公司 | 用于发现肿瘤特异性抗原和肿瘤特异性抗原决定簇的高产率t淋巴细胞克隆技术 |
| EP2242839A2 (en) * | 2008-02-11 | 2010-10-27 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods of obtaining antigen-specific t cell populations |
| US8383099B2 (en) * | 2009-08-28 | 2013-02-26 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Adoptive cell therapy with young T cells |
| US20120244133A1 (en) | 2011-03-22 | 2012-09-27 | The United States of America, as represented by the Secretary, Department of Health and | Methods of growing tumor infiltrating lymphocytes in gas-permeable containers |
| CN102816734A (zh) * | 2012-05-09 | 2012-12-12 | 阮润生 | 一种肿瘤抗原特异性t细胞的获取方法 |
-
2014
- 2014-07-14 CN CN201480044285.7A patent/CN105452448B/zh active Active
- 2014-07-14 RU RU2016103614A patent/RU2713333C2/ru active
- 2014-07-14 ES ES19209253T patent/ES2932429T3/es active Active
- 2014-07-14 EP EP22197914.9A patent/EP4137564B1/en active Active
- 2014-07-14 ES ES14745056T patent/ES2773548T3/es active Active
- 2014-07-14 CA CA2918080A patent/CA2918080A1/en active Pending
- 2014-07-14 CN CN202010606868.1A patent/CN111733131A/zh active Pending
- 2014-07-14 EP EP14745056.3A patent/EP3022294B1/en active Active
- 2014-07-14 ES ES22197914T patent/ES3034357T3/es active Active
- 2014-07-14 US US14/905,138 patent/US20160144018A1/en not_active Abandoned
- 2014-07-14 AU AU2014290286A patent/AU2014290286A1/en not_active Abandoned
- 2014-07-14 JP JP2016527005A patent/JP6616295B2/ja active Active
- 2014-07-14 WO PCT/US2014/046478 patent/WO2015009604A1/en not_active Ceased
- 2014-07-14 EP EP19209253.4A patent/EP3626817B1/en active Active
-
2018
- 2018-12-13 US US16/218,658 patent/US20190117761A1/en not_active Abandoned
-
2019
- 2019-11-07 JP JP2019202239A patent/JP7315435B2/ja active Active
-
2020
- 2020-09-16 AU AU2020233702A patent/AU2020233702B2/en active Active
- 2020-12-07 US US17/113,570 patent/US11077182B2/en active Active
-
2021
- 2021-07-12 US US17/372,927 patent/US11376318B2/en active Active
- 2021-07-12 US US17/373,093 patent/US11331385B2/en active Active
- 2021-07-12 US US17/373,130 patent/US11338032B2/en active Active
-
2022
- 2022-06-13 US US17/838,662 patent/US11918640B2/en active Active
-
2023
- 2023-09-22 AU AU2023233209A patent/AU2023233209B2/en active Active
-
2024
- 2024-02-01 US US18/430,031 patent/US12702706B2/en active Active
-
2026
- 2026-01-15 AU AU2026200282A patent/AU2026200282A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2016103614A (ru) | Способы получения т-клеток против антигена папилломавируса человека | |
| Tran et al. | Minimally cultured tumor-infiltrating lymphocytes display optimal characteristics for adoptive cell therapy | |
| Carrasco et al. | CD45RA on human CD8 T cells is sensitive to the time elapsed since the last antigenic stimulation | |
| EP4289944A3 (en) | Method for preparing genetically-modified t cells which express chimeric antigen receptor | |
| JP2016509840A5 (enExample) | ||
| JP2012521215A5 (enExample) | ||
| Klein et al. | EBV genome carrying B lymphocytes that express the nuclear protein EBNA-2 but not LMP-1: Type IIb latency | |
| CN109609451B (zh) | 体外快速扩增肾癌的肿瘤浸润淋巴细胞的方法 | |
| Chen et al. | Blocking IL-10 signalling at the time of immunization renders the tumour more accessible to T cell infiltration in mice | |
| EP4269595A3 (en) | Methods for selectively expanding cells expressing a tcr with a murine constant region | |
| JP2019508056A5 (enExample) | ||
| CN109294998B (zh) | 一种rff1细胞 | |
| CN113846059A (zh) | 3d肿瘤全抗原诱导激活的ctl细胞体外扩增培养方法 | |
| Klein et al. | Restricted expression of EBV encoded proteins in in vitro infected CLL cells | |
| Galluzzi et al. | Rejuvenated T cells attack old tumors | |
| CN120796184A (zh) | 一种用于扩增多能干细胞来源的nk细胞的非细胞刺激剂 | |
| HK40038785A (en) | Methods of preparing anti-human papillomavirus antigen t cells | |
| CN120699899A (zh) | 一种无血清特异性扩增获得强杀伤能力的Vγ9Vδ2T细胞的方法 | |
| Xu et al. | CD8+ memory T-cell inflation renders compromised CD4+ T-cell-dependent CD8+ T-cell immunity via naïve T-cell anergy | |
| Tano et al. | Enhancement of the T cell-stimulating ability of dendritic cells by 5-FU via regulation of the expression of ligands for programed cell death 1. | |
| CN104531616A (zh) | 缓释组分培养免疫细胞方法 | |
| Mohs et al. | Blockage of CCL5/RANTES modifies immune infiltration and the inflammatory milieu during chronic liver disease: 65 | |
| Mpunga et al. | Differential expression levels of activating and inhibitory receptors on NK cell subsets: Relevance to NK cell function | |
| Cho et al. | CT7 (MAGE-C1)-Specific Cellular Immune Responses in the Bone Marrow Microenvironment of Multiple Myeloma Patients. | |
| Magg et al. | 349: Ethylenecarbodiimide (ECDI) Coupled Allogeneic Antigen Presenting Cells Induce Human CD4+ Regulatory T Cells |